Acute myeloid leukemia pathophysiology: Difference between revisions

Jump to navigation Jump to search
(Category)
No edit summary
Line 1: Line 1:
<div style="-webkit-user-select: none;">
<div style="-webkit-user-select: none;">
{|class="infobox" style="position: fixed; top: 65%; right: 10px; margin: 0 0 0 0; border: 0; float: right;
{| class="infobox" style="position: fixed; top: 65%; right: 10px; margin: 0 0 0 0; border: 0; float: right;"
|-
|-
| {{#ev:youtube|https://https://www.youtube.com/watch?v=itkRVTqfPsE|350}}
| {{#ev:youtube|https://https://www.youtube.com/watch?v=itkRVTqfPsE|350}}
Line 19: Line 19:


* Modern classification schemes for acute myeloid leukemia recognize that the characteristics and behavior of the leukemic cell (and the leukemia) may depend on the stage at which differentiation was halted.
* Modern classification schemes for acute myeloid leukemia recognize that the characteristics and behavior of the leukemic cell (and the leukemia) may depend on the stage at which differentiation was halted.
=== Normal Hematopoeisis ===
* Hematopoeisis is tightly regulated under physiological conditions via a number of lineage-specific growth factor and lineage-specific growth signalling pathways.
* The differentiation of myeloid stem cells into mature myelocytes is controlled by lineage-specific transcription factors that regulate the expression of lineage-specific genes.


===Genetics===
===Genetics===
Specific [[cytogenetics|cytogenetic]] abnormalities can be found in many patients with acute myeloid leukemia; the types of chromosomal abnormalities often have [[prognosis|prognostic]] significance.<ref>Abeloff, Martin et al. (2004), pp. 2831&ndash;32.</ref>  The chromosomal [[translocations]] encode abnormal fusion [[proteins]], usually [[transcription factors]] whose altered properties may cause the "differentiation arrest."<ref>Greer, John P., et al. ''Wintrobe's Clinical Hematology'', 11th ed. Philadelphia: Lippincott, Williams, and Wilkins, 2004. p. 2045&ndash;2062</ref>  For example, in [[acute promyelocytic leukemia]], the t(15;17) translocation produces a PML-RARα [[fusion protein]] which binds to the [[retinoic acid]] receptor element in the promoters of several myeloid-specific genes and inhibits myeloid differentiation.<ref>Melnick A, Licht JD. Deconstructing a disease: RARα its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. ''Blood'' 1999;93:3167–3215. PMID 10233871</ref>. Acute myeloid leukemia M2 subtype is characterized by a [[translocation]] of a part of chromosome 8 to chromosome 21, written as t(8;21). On both sides of the chromosome, now containing pieces from two chromosomes, the DNA codes for different proteins. These two proteins are now being created as one single large protein, with a different effect in the body as the two proteins originally coded by the two different chromosomes. The two different proteins that are fused together are: [[RUNX1]] and ETO.
Specific [[cytogenetics|cytogenetic]] abnormalities can be found in many patients with acute myeloid leukemia; the types of chromosomal abnormalities often have [[prognosis|prognostic]] significance.<ref>Abeloff, Martin et al. (2004), pp. 2831&ndash;32.</ref>  The chromosomal [[translocations]] encode abnormal fusion [[proteins]], usually [[transcription factors]] whose altered properties may cause the "differentiation arrest."<ref>Greer, John P., et al. ''Wintrobe's Clinical Hematology'', 11th ed. Philadelphia: Lippincott, Williams, and Wilkins, 2004. p. 2045&ndash;2062</ref>  For example, in [[acute promyelocytic leukemia]], the t(15;17) translocation produces a PML-RARα [[fusion protein]] which binds to the [[retinoic acid]] receptor element in the promoters of several myeloid-specific genes and inhibits myeloid differentiation.<ref>Melnick A, Licht JD. Deconstructing a disease: RARα its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. ''Blood'' 1999;93:3167–3215. PMID 10233871</ref>. Acute myeloid leukemia M2 subtype is characterized by a [[translocation]] of a part of chromosome 8 to chromosome 21, written as t(8;21). On both sides of the chromosome, now containing pieces from two chromosomes, the DNA codes for different proteins. These two proteins are now being created as one single large protein, with a different effect in the body as the two proteins originally coded by the two different chromosomes. The two different proteins that are fused together are: [[RUNX1]] and ETO.


The clinical signs and symptoms of acute myeloid leukemia result from the fact that, as the leukemic clone of cells grows, it tends to displace or interfere with the development of normal blood cells in the bone marrow.<ref>
The clinical signs and symptoms of acute myeloid leukemia result from the fact that, as the leukemic clone of cells grows, it tends to displace or interfere with the development of normal blood cells in the bone marrow.<ref>Abeloff, Martin et al. (2004), p. 2828.</ref> This leads to [[neutropenia]], [[anemia]], and [[thrombocytopenia]].  The symptoms of acute myeloid leukemia are in turn often due to the low numbers of these normal blood elements.  In rare cases, patients can develop a ''[[chloroma]]'', or solid tumor of leukemic cells outside the bone marrow, which can cause various symptoms depending on its location.
Abeloff, Martin et al. (2004), p. 2828.</ref> This leads to [[neutropenia]], [[anemia]], and [[thrombocytopenia]].  The symptoms of acute myeloid leukemia are in turn often due to the low numbers of these normal blood elements.  In rare cases, patients can develop a ''[[chloroma]]'', or solid tumor of leukemic cells outside the bone marrow, which can cause various symptoms depending on its location.


===Microscopic Pathology===
===Microscopic Pathology===
Line 60: Line 63:


(Images shown below are courtesy of Melih Aktan MD., Istanbul Medical Faculty - Turkey, and Kyoto University - Japan)
(Images shown below are courtesy of Melih Aktan MD., Istanbul Medical Faculty - Turkey, and Kyoto University - Japan)
<gallery widths=200px>
<gallery widths="200px">
Image:AML 0.png|Acute myeloid leukemia-M0 - lack of obvious myeloid differentiation by routine histologic examination and presence of myeloperoxidase in <3% of blasts. Morphologically, blasts are small to large with no granules or Auer rods.
Image:AML 0.png|Acute myeloid leukemia-M0 - lack of obvious myeloid differentiation by routine histologic examination and presence of myeloperoxidase in <3% of blasts. Morphologically, blasts are small to large with no granules or Auer rods.
Image:Acute myeloid leukemia-M1 0002.jpg|Acute myeloid leukemia-M1 - presence of more than 90% myeloblasts in blood.
Image:Acute myeloid leukemia-M1 0002.jpg|Acute myeloid leukemia-M1 - presence of more than 90% myeloblasts in blood.
Line 100: Line 103:
{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Hematology]]
[[Category:Immunology]]

Revision as of 04:10, 17 September 2018

https://https://www.youtube.com/watch?v=itkRVTqfPsE%7C350}}

Acute myeloid leukemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Acute myeloid leukemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardigram

Chest X Ray

Echocardiograph and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Acute myeloid leukemia pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acute myeloid leukemia pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acute myeloid leukemia pathophysiology

CDC on Acute myeloid leukemia pathophysiology

Acute myeloid leukemia pathophysiology in the news

Blogs on Acute myeloid leukemia pathophysiology

Directions to Hospitals Treating Acute myeloid leukemia

Risk calculators and risk factors for Acute myeloid leukemia pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2] Carlos A Lopez, M.D. [3]

Overview

Acute myeloid leukemia arises from myeloblasts, which are hematologic white cells that are normally involved in hematopoiesis. Genetic translocations involved in the pathogenesis of acute myeloid leukemia include translocations between chromosome 8 and 21 t(8;21) and translocations between chromosome 15 and 17 t(15;17). Inversions in the chromosomal translocations in chromosome 16 inv(16) are also involved in the pathogenesis of acute myeloid leukemia.

Pathophysiology

  • The malignant cell in acute myeloid leukemia is the myeloblast. In normal hematopoiesis, the myeloblast is an immature precursor of myeloid white blood cells; a normal myeloblast will gradually mature into a mature white blood cell. However, in acute myeloid leukemia a single myeloblast accumulates genetic changes which "freeze" the cell in its immature state and prevent differentiation.[1] Such a mutation alone does not cause leukemia; however, when such a "differentiation arrest" is combined with other mutations which disrupt genes controlling proliferation, the result is the uncontrolled growth of an immature clone of cells, leading to the clinical entity of acute myeloid leukemia.[2]
  • Much of the diversity and heterogeneity of acute myeloid leukemia stems from the fact that leukemic transformation can occur at a number of different steps along the differentiation pathway.[3]
  • Modern classification schemes for acute myeloid leukemia recognize that the characteristics and behavior of the leukemic cell (and the leukemia) may depend on the stage at which differentiation was halted.

Normal Hematopoeisis

  • Hematopoeisis is tightly regulated under physiological conditions via a number of lineage-specific growth factor and lineage-specific growth signalling pathways.
  • The differentiation of myeloid stem cells into mature myelocytes is controlled by lineage-specific transcription factors that regulate the expression of lineage-specific genes.

Genetics

Specific cytogenetic abnormalities can be found in many patients with acute myeloid leukemia; the types of chromosomal abnormalities often have prognostic significance.[4] The chromosomal translocations encode abnormal fusion proteins, usually transcription factors whose altered properties may cause the "differentiation arrest."[5] For example, in acute promyelocytic leukemia, the t(15;17) translocation produces a PML-RARα fusion protein which binds to the retinoic acid receptor element in the promoters of several myeloid-specific genes and inhibits myeloid differentiation.[6]. Acute myeloid leukemia M2 subtype is characterized by a translocation of a part of chromosome 8 to chromosome 21, written as t(8;21). On both sides of the chromosome, now containing pieces from two chromosomes, the DNA codes for different proteins. These two proteins are now being created as one single large protein, with a different effect in the body as the two proteins originally coded by the two different chromosomes. The two different proteins that are fused together are: RUNX1 and ETO.

The clinical signs and symptoms of acute myeloid leukemia result from the fact that, as the leukemic clone of cells grows, it tends to displace or interfere with the development of normal blood cells in the bone marrow.[7] This leads to neutropenia, anemia, and thrombocytopenia. The symptoms of acute myeloid leukemia are in turn often due to the low numbers of these normal blood elements. In rare cases, patients can develop a chloroma, or solid tumor of leukemic cells outside the bone marrow, which can cause various symptoms depending on its location.

Microscopic Pathology

Description of pictures according the classification of Acute myeloid leukemia system.

Acute myeloid leukemia M0 classification

  • Acute myeloid leukemia M0 with lack of obvious myeloid differentiation by routine histologic examination and presence of myeloperoxidase in <3% of blasts. Morphologically, blasts are small to large with no granules or Auer rods.
  • Acute myeloid leukemia-M1 with presence of more than 90% myeloblasts in blood.
  • Acute myeloid leukemia-M1 peroxidase.

Acute myeloid leukemia M2 classification

  • Acute myeloid leukemia-M2: Presence of granules can be noted.
  • Acute myeloid leukemia-M2: Large myeloblasts with prominent nucleoli.

Acute myeloid leukemia M3 classification

  • Acute myeloid leukemia-M3: Also called promyelocytic leukemia. Hypergranular morphology with most cells containing abundant large granules.
  • Acute myeloid leukemia-M3: Ruptured cells are releasing their granules free onto the slide. Presence of Auer rods can be noticed.

Acute myeloid leukemia M5a and M5b classification

  • Acute myeloid leukemia-M5a: >80% monoblasts in the marrow.
  • Acute myeloid leukemia-M5a: large monoblasts with fine nuclear chromatin and prominent nucleoli. Note the absence of Auer rods.
  • Acute myeloid leukemia-M5b: <80% monoblasts in the marrow.

Acute myeloid leukemia M7 classification

  • Acute myeloid leukemia-M7: Irregular cytoplasmic border is often noted in some of the megakaryoblasts and occasionally projections resembling budding atypical platelets are present.
    • Megakaryoblasts are usually medium-sized to large cells with a high nuclear-cytoplasmic ratio
    • Nuclear chromatin is dense and homogeneous
    • Variable basophilic cytoplasm which may be vacuolated
    • An irregular cytoplasmic border is often noted in some of the megakaryoblasts and occasionally projections resembling budding atypical platelets are present
    • Megakaryoblasts lack myeloperoxidase (MPO) activity and stain negatively with Sudan black B
    • Clumps or granules in the cytoplasm
    • PAS staining varies from negative to focal or granular positivity, to strongly positive staining
    • More precise identification is by immunophenotyping or with electron microscopy (EM)
    • Immunophenotyping using MoAb to megakaryocytic restricted antigen (CD41 and CD61) may be diagnostic

(Images shown below are courtesy of Melih Aktan MD., Istanbul Medical Faculty - Turkey, and Kyoto University - Japan)

References

  1. Fialkow PJ: Clonal origin of human tumors. Biochim Biophys Acta 1976;458:283–321. PMID 1067873
  2. Fialkow PJ, Janssen JW, Bartram CR: Clonal remissions in acute nonlymphocytic leukemia: Evidence for a multistep pathogenesis of the malignancy. Blood 1991;77:1415–1517. PMID 2009365
  3. Bonnet D, Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730–737. PMID 9212098
  4. Abeloff, Martin et al. (2004), pp. 2831–32.
  5. Greer, John P., et al. Wintrobe's Clinical Hematology, 11th ed. Philadelphia: Lippincott, Williams, and Wilkins, 2004. p. 2045–2062
  6. Melnick A, Licht JD. Deconstructing a disease: RARα its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999;93:3167–3215. PMID 10233871
  7. Abeloff, Martin et al. (2004), p. 2828.

Template:Hematology


Template:WikiDoc Sources